Thrombotic, Inflammatory & Gene Markers of CVD in Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00006539|
Recruitment Status : Completed
First Posted : November 28, 2000
Last Update Posted : March 16, 2016
|Condition or disease|
|Cardiovascular Diseases Heart Diseases Myocardial Infarction Postmenopause|
Over the past 50 years, considerable progress has been made in understanding factors that stimulate the development of atherosclerosis and other manifestations of "preclinical cardiovascular disease," and in documenting the 2- to 4-fold higher risk of subsequent myocardial infarction or other morbid events in asymptomatic individuals with such pathological transformations in arteries or the heart. However, much less information is available about the factors ("triggers") that precipitate morbid and mortal events in high-risk individuals. Recent work by Paul Ridker and colleagues and other groups has identified associations between the presence of markers of prothrombotic tendencies, inflammation and immune activation and myocardial infarction and other cardiovascular disease (CVD) events. However, most available data have been obtained in men and less is known about the relevance of these newer risk factors and potential "triggers" to stimulation of atherosclerosis and precipitation of CVD events in women. In this context, research to examine the relation of both relatively new and potentially novel "triggers" to subsequent myocardial infarction in women is of considerable potential clinical and biological significance.
Drs. Ridker and colleagues comprehensively evaluated a series of thrombotic, inflammatory, and genetic markers for myocardial infarction (MI) among participants in the Women's Health Initiative Observational Study (WHI-OS), a prospective cohort study of over 90,000 ethnically representative post-menopausal American women aged 50-79 years. Employing a prospective nested case-control design, they assayed baseline plasma and buffy coat samples for nine markers of increased thrombotic potential (tissue-type plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1), total plasma homocysteine, prothrombin fragment F1+2, D-dimer, APC-R, C-reactive protein, interleukin-6, and sICAM-1) to determine whether elevations of these parameters led to future MI or coronary death. They also explored common genetic polymorphisms in the tPA, PAI-1, MTHFR, thrombomodulin, prothrombin, and factor V genes so that both inherited and environmental determinants of coronary thrombosis in women could simultaneously be evaluated. Case subjects were WHI-OS participants who were free of cardiovascular disease at study entry and subsequently developed a documented MI or coronary death during follow-up (N = 650). Control subjects were selected from study participants who remained free of disease during follow-up; controls were 1:1 matched to cases by age, smoking status, ethnicity, and follow-up time. Data on usual risk factors, hormone replacement therapy, and standard lipid profiles were used to evaluate for potential confounding and effect modification. The analyses took advantage of a unique and unprecedented blood bank from a well-characterized, ethnically diverse, large-scale cohort of post-menopausal women with ongoing follow-up and high quality endpoint verification, thereby providing an efficient way to critically evaluate the hypothesized roles of hemostasis, thrombosis and inflammation as risk factors for future MI and coronary death among American women.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
|Study Type :||Observational|
|Study Start Date :||September 1999|
|Study Completion Date :||August 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006539
|OverallOfficial:||Paul Ridker||Brigham and Women's Hospital|